Dianthus Therapeutics (DNTH) Change in Accured Expenses (2017 - 2023)

Dianthus Therapeutics' Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$1.7 million for Q2 2023.

• In Q2 2023, Change in Accured Expenses fell 169.82% year-over-year to -$1.7 million; the TTM figure through Jun 2023 stood at -$2.6 million (down 48.18% YoY), while the FY2022 annual figure was $973000.0, up 535.95% from the prior year.
• Change in Accured Expenses for Q2 2023 stood at -$1.7 million, up from -$3.3 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $3.7 million in Q4 2019, with the low at -$3.3 million in Q1 2023.
• The 5-year median for Change in Accured Expenses is -$260500.0 (2020), against an average of -$135444.4.
• The sharpest annual moves came in 2019 and 2023: Change in Accured Expenses soared 643.89% in 2019, then slumped 288.71% in 2023.
• Dianthus Therapeutics' Change in Accured Expenses stood at $3.7 million in 2019, then plunged by 93.13% to $255000.0 in 2020, then plunged by 271.76% to -$438000.0 in 2021, then jumped by 446.8% to $1.5 million in 2022, then slumped by 210.66% to -$1.7 million in 2023.
• Business Quant data shows DNTH's Change in Accured Expenses at -$1.7 million in Q2 2023, -$3.3 million in Q1 2023, and $1.5 million in Q4 2022.